Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-01-01 Epub Date: 2024-12-08 DOI:10.1080/14796694.2024.2435253

Paul Cockrum, Syvart Dennen, Audrey Brown, Jonathon Briggs, Ravi Paluri

{"title":"Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.","authors":"Paul Cockrum, Syvart Dennen, Audrey Brown, Jonathon Briggs, Ravi Paluri","doi":"10.1080/14796694.2024.2435253","DOIUrl":null,"url":null,"abstract":"Aims: This systematic review summarizes real-world clinical outcomes and economic burden of first-line FOLFIRINOX (FFX)/modified FFX (mFFX) and nab-paclitaxel plus gemcitabine (GnP) in metastatic pancreatic ductal adenocarcinoma in the US.Methods: Embase and MEDLINE were searched for materials published since 2014; citations were reviewed in a two-step process. Included studies were qualitatively synthesized.Results: Searches yielded 2,528 citations; 29 were included (17 clinical studies/12 economic studies). In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months; for GnP mOS ranged from 3.6 to 9.8 months, and the unweighted median of the estimates was 6.9 months. In 8/17 studies, grade 3/4 anemia, neutropenia, and thrombocytopenia were the most commonly reported adverse events. Across economic burden studies, total costs were similar between the 2 groups. Outpatient, supportive care, and granulocyte colony-stimulating factor costs were higher for the FFX generic regimen, and chemotherapy costs were higher for the GnP branded regimen.Conclusions: Real-world OS in FFX- and GnP-treated populations was shorter than that in clinical trials, and total costs of FFX and GnP were similar, but with differences in cost components.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"241-260"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792790/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2435253","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This systematic review summarizes real-world clinical outcomes and economic burden of first-line FOLFIRINOX (FFX)/modified FFX (mFFX) and nab-paclitaxel plus gemcitabine (GnP) in metastatic pancreatic ductal adenocarcinoma in the US.

Methods: Embase and MEDLINE were searched for materials published since 2014; citations were reviewed in a two-step process. Included studies were qualitatively synthesized.

Results: Searches yielded 2,528 citations; 29 were included (17 clinical studies/12 economic studies). In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months; for GnP mOS ranged from 3.6 to 9.8 months, and the unweighted median of the estimates was 6.9 months. In 8/17 studies, grade 3/4 anemia, neutropenia, and thrombocytopenia were the most commonly reported adverse events. Across economic burden studies, total costs were similar between the 2 groups. Outpatient, supportive care, and granulocyte colony-stimulating factor costs were higher for the FFX generic regimen, and chemotherapy costs were higher for the GnP branded regimen.

Conclusions: Real-world OS in FFX- and GnP-treated populations was shorter than that in clinical trials, and total costs of FFX and GnP were similar, but with differences in cost components.

查看原文本刊更多论文

真实世界的临床结果和转移性胰腺导管腺癌的经济负担：一项系统综述。

目的：这篇系统综述总结了美国转移性胰腺导管腺癌一线FOLFIRINOX（FFX）/改良FFX（mFFX）和纳布紫杉醇加吉西他滨（GnP）的实际临床结果和经济负担：检索Embase和MEDLINE中2014年以来发表的资料；分两步审查引文。对纳入的研究进行定性综合：结果：检索到 2,528 篇引文，纳入 29 篇（17 篇临床研究/12 篇经济研究）。在 9/17 项临床研究中，FFX/mFFX 的中位总生存期（mOS）从 4.7 个月到 11.4 个月不等，在此范围内估计值的非加权中位数为 9.2 个月；GnP 的中位总生存期（mOS）从 3.6 个月到 9.8 个月不等，估计值的非加权中位数为 6.9 个月。在 8/17 项研究中，3/4 级贫血、中性粒细胞减少症和血小板减少症是最常报告的不良事件。在所有经济负担研究中，两组的总成本相似。FFX通用方案的门诊、支持治疗和粒细胞集落刺激因子费用较高，而GnP品牌方案的化疗费用较高：结论：FFX和GnP治疗人群的实际OS短于临床试验，FFX和GnP的总成本相似，但成本构成不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.